October 2018, Volume 4, Issue 12

October 2018

Volume 4, Issue 12

This issue features a look at the Right to Try debate, a breakdown of how epigenetics are used in hematology, and more.

Table of Contents

October 2018 Issue

Recommendations from My Bookshelf: A Bloody Mess

Friday, September 28th, 2018
Imagine that you’re young, brilliant, charismatic, and you have a compelling vision for a bold new idea that could revolutionize health care: scores of...

October 2018 Issue

Announcing the 2018 Honorific and Mentor Award Recipients, and more

Friday, September 28th, 2018
Announcing the 2018 Honorific and Mentor Award Recipients!  ASH will recognize these distinguished leaders in hematology through awards and special lectures at the 60th ASH...

Jonas Sokolof Named Director of NYU Langone’s New Rehab Program for Cancer Survivors, and...

Friday, September 28th, 2018
Jonas Sokolof Appointed Director of NYU Langone’s New Rehabilitation Program for Cancer Survivors  NYU Langone’s Rusk Rehabilitation has opened the Division of Oncological Rehabilitation, launching...

October 2018 Issue

The Realities of “Right to Try”

Friday, September 28th, 2018
In May 2018, President Donald Trump signed into law the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of...

Let’s Get Cooking: Jonathan Hoggatt, PhD

Friday, September 28th, 2018
In this edition, Jonathan G. Hoggatt, PhD, discusses his passion for the delicious art of cooking. Hear more from our interview with Dr. Hoggatt in...

Pulling Back the Curtain: Vip Viprakasit, MD, DPhil

Friday, September 28th, 2018
In this edition, Vip Viprakasit, MD, DPhil, talks about working in a limited-resource setting, falling in love with the red cell, and his surprising...

October 2018 Issue

Demystifying Epigenetics in Hematology

Friday, September 28th, 2018
In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...

How would you treat a patient with autoimmune hepatitis, grade 4 cirrhosis, and declining...

Friday, September 28th, 2018
Here’s how readers responded to a You Make the Call question about a 22-year-old patient presenting with epistaxis, a platelet count of zero, abnormal...

How would you treat a patient with autoimmune hepatitis, grade 4 cirrhosis, and declining...

Friday, September 28th, 2018
This month, Spero Cataland, MD, discusses whether a patient with thrombocytopenia has hypersplenism, immune thrombocytopenia, or both. And don't forget to check out next month's...

October 2018 Issue

WIB_icon

Mapping Silent Cerebral Infarcts in Children With Sickle Cell Anemia

Friday, September 28th, 2018
Children with sickle cell anemia (SCA) are at risk of developing cerebral ischemia, including a high prevalence of silent cerebral infarcts (SCI), which can...

Phase I Trial Shows Activity of Single-Agent Ivosidenib in IDH1-Mutated AML

Friday, September 28th, 2018
Ivosidenib was safe and associated with remissions, transfusion independence, and molecular remissions in patients with relapsed or refractory IDH1-mutated acute myeloid leukemia (AML), according...

Oral L-Glutamine Powder Lowers Frequency of Sickle Cell–Related Pain Episodes

Friday, September 28th, 2018
Oral L-glutamine powder, with or without hydroxyurea, reduced the number of pain events experienced by children and adults with sickle cell disease (SCD), compared...

FDA Warns Against Using Azithromycin After Stem Cell Transplant

Friday, September 28th, 2018
The U.S. Food and Drug Administration (FDA) issued a statement advising clinicians to avoid using the antibiotic azithromycin in patients with certain cancers who...

Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma

Friday, September 28th, 2018
While clinical trials of the proteasome inhibitor carfilzomib for the treatment of multiple myeloma (MM) showed varying incidence rates of cardiovascular adverse events (AEs),...

FDA Approves Mogamulizumab-kpkc for Two Types of Non-Hodgkin Lymphoma

Friday, September 28th, 2018
The U.S. Food and Drug Administration (FDA) approved mogamulizumab-kpkc for intravenous use in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome...

Can a Liquid Biopsy Predict Outcomes in DLBCL?

Friday, September 28th, 2018
In a study of patients with diffuse large B-cell lymphoma (DLBCL), levels of pretreatment circulating tumor DNA (ctDNA) and molecular responses were independent predictors...

New Immunotherapy Approach Shows Activity in NCI Trials

Friday, September 28th, 2018
Treatment with tumor-infiltrating lymphocytes (TILs), a new type of immunotherapy, induced complete remission in a patient with breast cancer, according to a report by...

Lusutrombopag Approved for Thrombocytopenia in Chronic Liver Disease

Friday, September 28th, 2018
The U.S. Food and Drug Administration has approved lusutrombopag for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to...

FDA Approves Second Filgrastim Biosimilar

Friday, September 28th, 2018
Filgrastim-aafil received approval from the U.S. Food and Drug Administration (FDA), making it the second approved biosimilar version of filgrastim. The treatment was given...

October 2018 Issue

From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal...

Friday, September 28th, 2018
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

From ASH Meeting on Hematologic Malignancies: Treating “Problematic” Cases of Polycythemia Vera

Friday, September 28th, 2018
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

From ASH Meeting on Hematologic Malignancies: Treating a Young Patient With Newly Diagnosed ALL

Friday, September 28th, 2018
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

SHARE